| [1] | Tsokos GC. Systemic lupus erythematosus[J]. N Engl J Med, 2011, 365: 2110-2121. doi: 10.1056/NEJMra1100359
 | 
																													
																						| [2] | 周纬, 殷蕾, 金燕樑. 儿童系统性红斑狼疮临床特征(附47例报告)[J]. 上海医学, 2008, 31(12): 843-845. | 
																													
																						| [3] | Kamphuis S, Silverman ED. Prevalence and burden of pediatric onset systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2010, 6: 538-546. doi: 10.1038/nrrheum.2010.121
																																					pmid: 20683438
 | 
																													
																						| [4] | 殷蕾, 周纬. 系统性红斑狼疮危象[J]. 中国小儿急救医学, 2020, 27(5): 324-329. | 
																													
																						| [5] | Kazzaz NM, Coit P, Lewis EE, et al. Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival[J]. Lupus Sci Med, 2015, 2(1): e000117. | 
																													
																						| [6] | Ju JH, Min JK, Jung CK, et al. Lupus mesenteric vasculitis can cause acute abdominal pain in patients with SLE[J]. Nat Rev Rheumatol, 2009, 5(5): 273-281. doi: 10.1038/nrrheum.2009.53
																																					pmid: 19412194
 | 
																													
																						| [7] | Alperin JM, Ortiz-Fernández L, Sawalha AH. Monogenic lupus: a developing paradigm of disease[J]. Front Immunol, 2018, 9: 2496. doi: 10.3389/fimmu.2018.02496
																																					pmid: 30459768
 | 
																													
																						| [8] | Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78: 1151-1159. doi: 10.1136/annrheumdis-2018-214819
																																					pmid: 31383717
 | 
																													
																						| [9] | Al-Mayouf SM, Akbar L, Abdwani R, et al. Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematous in monogenic lupus[J]. Clin Rheumatol, 2022, doi: 10.1007/s10067-022-06209-9. doi: 10.1007/s10067-022-06209-9
 | 
																													
																						| [10] | 中华医学会儿科学分会免疫学组中华儿科杂志编辑委员会. 中国儿童系统性红斑狼疮诊断与治疗指南[J]. 中华儿科杂志, 2021, 59(12) : 1009-1024. | 
																													
																						| [11] | Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus[J]. Arthritis Rheum, 1996, 39: 363-369. doi: 10.1002/art.1780390303
 | 
																													
																						| [12] | Petri M, Magder LS. Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort[J]. Arthritis Rheumatol, 2018, 70: 1790-1795. doi: 10.1002/art.40571
 | 
																													
																						| [13] | Wahadat MJ, van den Berg L, Timmermans D, et al. LLDAS is an attainable treat-to-target goal in childhood-onset SLE[J]. Lupus Sci Med, 2021, 8(1): e000571. | 
																													
																						| [14] | FranklynK, LauCS, NavarraSV, et al. Definition and initial validation of a lupus low disease activity state (LLDAS)[J]. Anna Rheuma Dis, 2015, 75 (9): 1615. | 
																													
																						| [15] | van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)[J]. Ann Rheum Dis, 2017, 76: 554-561. doi: 10.1136/annrheumdis-2016-209519
																																					pmid: 27884822
 | 
																													
																						| [16] | Atar D, Birkeland KI, Uhlig T. 'Treat to target': moving targets from hypertension, hyperlipidaemia and diabetes to heumatoid arthritis[J]. Ann Rheum Dis, 2010, 69: 629-630. doi: 10.1136/ard.2010.128462
																																					pmid: 20237122
 | 
																													
																						| [17] | Kumar K, Gordon C, Toescu V, et al. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of south Asian and White British origin[J]. Rheumatology (Oxford), 2008, 47: 690-697. doi: 10.1093/rheumatology/ken050
																																					pmid: 18375972
 | 
																													
																						| [18] | Mok CC, Hamijoyo L, Kasitanon N, et al. The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus[J]. Lancet Rheumatol, 2021, 3: e517-e531. | 
																													
																						| [19] | Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review[J]. Ann Rheum Dis, 2010, 69: 20-28. doi: 10.1136/ard.2008.101766
																																					pmid: 19103632
 | 
																													
																						| [20] | Mok CC, Yap DY, Navarra SV, et al. Overview of lupus nephritis management guidelines and perspective from Asia[J]. Int J Rheum Dis, 2013, 16(6): 625-636. doi: 10.1111/1756-185X.12212
																																					pmid: 24382275
 | 
																													
																						| [21] | Buttgereit F, Straub RH, Wehling M, et al. Glucocorticoids in the treatment of rheumatic diseases:an update on the mechanisms of action[J]. Arthritis Rheum, 2004, 50: 3408-3417. doi: 10.1002/art.20583
 | 
																													
																						| [22] | Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78: 736-745. doi: 10.1136/annrheumdis-2019-215089
																																					pmid: 30926722
 | 
																													
																						| [23] | KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases[J]. Kidney Int, 2021, 100(4S): S1-S276. | 
																													
																						| [24] | Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis[J]. N Engl J Med, 2005, 353: 2219-2228. doi: 10.1056/NEJMoa043731
 | 
																													
																						| [25] | Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study[J]. Rheumatology (Oxford), 2010, 49: 128-140. doi: 10.1093/rheumatology/kep346
																																					pmid: 19933596
 | 
																													
																						| [26] | 王笑秋, 殷蕾, 茅幼英, 等. 多靶点治疗儿童狼疮肾炎的疗效观察[J]. 中华风湿病学杂志, 2014, 18(9): 47-51. | 
																													
																						| [27] | Weidenbusch M, Römmele C, Schröttle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis[J]. Nephrol Dial Transplant, 2013, 28: 106-111. doi: 10.1093/ndt/gfs285
 | 
																													
																						| [28] | Lorenz G, Schul L, Schraml F, et al. Adult macro-phage activation syndrome-haemophagocytic lymphohistiocytosis: ‘of plasma exchange and immunosuppressive escalation strategies’ - a single centre reflection[J]. Lupus, 2020, 29: 324-333. doi: 10.1177/0961203320901594
																																					pmid: 32013725
 |